EFFECT OF CURCUMIN ON GLYCEMIC CONTROL AND METABOLIC PARAMETERS IN PREDIABETES AND DIABETES
Article Sidebar
Main Article Content
Abstract
The trend of adding natural medicines for diabetes treatment is uprising. Curcumin, commercially available as mixture of curcuminoids, is one of natural substance which has antidiabetic activities including insulin secretagogue and insulin sensitizer. Possible mechanisms include attenuation of tumor necrosis factor-alpha (TNF-α) and plasma free fatty acid (FFA) as well as activation of peroxisome proliferator-activated receptor gamma (PPAR-γ). This systematic review was aimed to evaluate the effect of curcumin on glycemic control and metabolic parameters in prediabetes and diabetes. Literature review up to November 2017 was undertaken in Pubmed, Cochrane Central Register of Controlled Trials (CENTRAL), The Cumulative Index to Nursing and Allied Health Literature (CINAHL), National Center for Complementary and Integrative Health (NCCIH), Scopus, ScienceDirect, Web of Science, ProQuest Dissertations and Theses (PQDT), etc. Twelve trials (N=459) met the eligibility criteria and were included. The results indicated that curcuminoids may offer benefits for prediabetes and type 2 diabetes mellitus (T2DM) with tolerable safety profile. Regardless of the varied settings of the included trials, curcuminoids tended to reduce fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) in these populations. Additionally, the improvement was likely observed on lipid profile, such as triglyceride and cholesterol. The available evidence also suggested that giving curcuminoids might be a good strategy to prevent the development of T2DM in prediabetes. Notwithstanding the beneficial effects of curcumin on glycemic control and lipid profile, the recent data may encourage higher quality trials with longer duration to establish the role of curcumin in clinical application, particularly in diabetes management.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Journal of TCI is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence, unless otherwise stated. Please read our Policies page for more information.
References
Adab, Z., Eghtesadi, S., Vafa, M., Heydari, I., Shojaei, A., Haqqani, H., et al. 2013. Effect of turmeric on body measurement indices, glycemic condition, and lipid profile in hyperlipidemic patients with type 2 diabetes. Iran J. Nutr. Sci. Food Technol. 8(3): 217-27.
American Diabetes Association. 2017. Standards of medical care in diabetes-2017. Diabetes Care. 40(1): S1-135.
Banerji, S., & Banerjee, S. 2016. A formulation of grape seed, Indian gooseberry, turmeric and fenugreek helps controlling type 2 diabetes mellitus in advanced-stage patients. Eur J Integr Med. 8(5): 645-53.
Bi, X., Lim, J., & Henry, C. J. 2017. Spices in the management of diabetes mellitus. Food Chem. 217(-): 281-93.
Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., Phisalaphong, C., & Jirawatnotai, S. 2012. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 35(11): 2121-7.
Chuengsamarn, S., Rattanamongkolgul, S., Phonrat, B., Tungtrongchitr, R., & Jirawatnotai, S. 2014. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: A randomized controlled trial. J. Nutr. Biochem. 25(2): 144-50.
Cicero, A. F. G., Fogacci, F., Morbini, M., Colletti, A., Bove, M., Veronesi, M., et al. 2017. Nutraceutical effects on glucose and lipid metabolism in patients with impaired fasting glucose: A pilot, double-blind, placebo-controlled, randomized clinical trial on a combined product. High Blood Press. Cardiovasc. Prev. 24(3): 283–88.
Del Prato, S., Bianchi, C., & Daniele, G. 2017. Abnormalities of insulin secretion and β-cell defects in type 2 diabetes. In: Holt, R. I. G., Cockram, C. S., Flyvbjerg, A. & Goldstein, B. J., editors, Textbook of Diabetes 5 ed. Chicester (UK): John Wiley & Sons, Ltd; pp. 161-73.
Ghorbani, Z., Hekmatdoost, A., & Mirmiran, P. 2014. Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin. Int J Endocrinol Metab. 12(4): e18081.
Grant, S. J., Chang, D. H., Liu, J., Wong, V., Kiat, H., & Bensoussan, A. 2013. Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial. BMC Complement. Altern. Med. 13(-): 104.
Higgins, J. P. T., Altman, D. G., & editors. 2008. Chapter 8: Assessing risk of bias in included studies. In J. P. T. Higgins & S. Green editors, Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons; pp. 187-241.
Hodai, H., Adibian, M., & Sohrab, G. 2016. Effects of curcumin supplementation on BMI and blood pressure in patients with type 2 diabetes. Abstract presented at The World Congress on Clinical Trials in Diabetes 2016, Berlin, Germany. Endocrine Abstracts. 43. pp. OC51.
Hodaie, H., Adibian, M., Sohrab, G., & Hedayati, M. 2017. The effects of curcumin supplementation on control glycemic and anthropometric indices in overweight patients with type 2 diabetes. Iran J. Endocrinol. Metab. 19(1): 1-9.
Jiménez-Osorio, A. S., García-Niño, W. R., González-Reyes, S., Álvarez-Mejía, A. E., Guerra-León, S., Salazar-Segovia, J., et al. 2016. The effect of dietary supplementation with curcumin on redox status and nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J. Ren. Nutr. 26(4): 237-44.
Khajehdehi, P., Pakfetrat, M., Javidnia, K., Azad, F., Malekmakan, L., Nasab, M. H., et al. 2011. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand. J. Urol. Nephrol. 45(5): 365-70.
Kurian, G. A., Manjusha, V., Nair, S. S., Varghese, T., & Padikkala, J. 2014. Short-term effect of g-400, polyherbal formulation in the management of hyperglycemia and hyperlipidemia conditions in patients with type 2 diabetes mellitus. Nutrition. 30(10): 1158-64.
Lee, M. S., Wahlqvist, M. L., Chou, Y. C., Fang, W. H., Lee, J. T., Kuan, J. C., et al. 2014. Turmeric improves post-prandial working memory in pre-diabetes independent of insulin. Asia Pac. J. Clin. Nutr. 23(4): 581-91.
Mahajan, S., Chauhan, P., Subramani, S. K., Anand, A., Borole, D., Goswamy, H., et al. 2015. Evaluation of “GSPF kwath”: a gymnema sylvestre-containing polyherbal formulation for the treatment of human type 2 diabetes mellitus. Eur. J. Integr. Med. 7(3): 303-11.
Mani, U. V., Iyer, U., Mani, I., & Desikachar, H. S. R. 1997. Long-term effect of cereal-pulse mix (diabetic mix) supplementation on serum lipid profile in non-insulin-dependent diabetes mellitus patients. J. Nutr. Environ. Med. 7(3): 163-68.
Na, L. X., Li, Y., Pan, H. Z., Zhou, X. L., Sun, D. J., Meng, M., et al. 2013. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol. Nutr. Food Res. 57(9): 1569-77.
Nakayama, H., Tsuge, N., Sawada, H., Masamura, N., Yamada, S., Satomi, S., et al. 2014. A single consumption of curry improved postprandial endothelial function in healthy male subjects: a randomized, controlled crossover trial. Nutr. J. 13(1): 67-67.
Neerati, P., Devde, R., & Gangi, A. K. 2014. Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus. Phytother. Res. 28(12): 1796-800.
Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Soflaei, S. S., Majeed, M., et al. 2016a. Effects of supplementation with curcumin on serum adipokine concentrations: a randomized controlled trial. Nutrition. 32(10): 1116-22.
Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L. E., & Sahebkar, A. 2016b. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J. Cardiovasc. Pharmacol. 68(3): 223-29.
Panahi, Y., Khalili, N., Sahebi, E., Namazi, S., Karimian, M. S., Majeed, M., et al. 2017a. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology. 25(1): 25-31.
Panahi, Y., Khalili, N., Sahebi, E., Namazi, S., Reiner, Majeed, M., et al. 2017b. Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial. Complement. Ther. Med. 33(-): 1-5.
Prasad, S., Gupta, S. C., Tyagi, A. K., & Aggarwal, B. B. 2014. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol. Adv. 32(6): 1053-64.
Rahimi, H. R., Mohammadpour, A. H., Dastani, M., Jaafari, M. R., Abnous, K., Ghayour Mobarhan, M., et al. 2016. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J. Phytomed. 6(5): 567-77.
Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A., et al. 2016. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother. Res. 30(-): 1540-48.
Rotman-Pikielny, P., Ness-Abramof, R., Charach, G., Roitman, A., Zissin, R., & Levy, Y. 2014. Efficacy and safety of the dietary supplement DBCare(R) in patients with type 2 diabetes mellitus and inadequate glycemic control. J. Am. Coll. Nutr. 33(1): 55-62.
Selvi, N. M. K., Sridhar, M. G., Swaminathan, R. P., & Sripradha, R. 2015. Efficacy of turmeric as adjuvant therapy in type 2 diabetic patients. Indian J. Clin. Biochem. 30(2): 180-86.
Sengupta, K., Mishra, A. T., Rao, M. K., Sarma, K. V., Krishnaraju, A. V., & Trimurtulu, G. 2012. Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study. Lipids Health Dis. 11(1): 122-31.
Setiawan, A. S., Yulinah, E., Adnyana, I. K., Permana, H., & Sudjana, P. 2011. Antidiabetic effect of garlic extract (Allium sativum Linn.) and curcumin extract (Curcuma domestica Val.) combination compared to glibenclamide in type 2 diabetes meliitus. MKB. 43(1): 26-34.
Steigerwalt, R., Nebbioso, M., Appendino, G., Belcaro, G., Ciammaichella, G., Cornelli, U., et al. 2012. Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Med. 54(4): 11.
Sukandar, E. Y., Permana, H., Adnyana, I. K., Sigit, J. I., Ilyas, R. A., Hasimun, P., et al. 2010. Clinical study of turmeric (Curcuma longa L.) and Garlic (Allium sativum L.) extracts as antihyperglycemic and antihyperlipidemic agent in type-2 diabetes-dyslipidemia patients. Int. J. Pharm. 6(4): 438-45.
Sukandar, E. Y., Sudjana, P., Adnyana, I. K., Setiawan, A. S., & Yuniarni, U. 2014. Recent study of turmeric in combination with garlic as antidiabetic agent. Procedia Chem. 13(Supplement C): 44-56.
Usharani, P., Mateen, A. A., Naidu, M. U., Raju, Y. S., & Chandra, N. 2008. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R. D. 9(4): 243-50.
Wickenberg, J., Ingemansson, S. L., & Hlebowicz, J. 2010. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr. J. 9(-): 43.
World Health Organization. Global report on diabetes. 2016. (Accessed on Oct 31, 2017, at http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf).
Yang, H., Xu, W., Zhou, Z., Liu, J., Li, X., Chen, L., et al. 2015. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. Exp. Clin. Endocrinol. Diabetes. 123(06): 360-67.
Yang, Y. S., Su, Y. F., Yang, H. W., Lee, Y. H., Chou, J. I., & Ueng, K. C. 2014. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother. Res. 28(12): 1770-77.
Zhang, D. W., Fu, M., Gao, S. H., & Liu, J. L. 2013. Curcumin and diabetes: a systematic review. Evid. Based Complement. Alternat. Med. 2013(-): 636053.